ELI LILLY & (LLY) Company Report

Lilly’s Q4 revenue rose 43% to $19.3 billion, with adjusted EPS of $7.54, both topping estimates.
GLP-1 blockbusters Mounjaro and Zepbound drove growth, generating $7.41 billion and $4.26 billion, respectively, in the quarter.
The company raised its 2026 outlook to $80–$83 billion in revenue and $33.50–35 in adjusted EPS.
Adjusted operating margins expanded by nearly 300 bps, though the CFO warned pricing pressure will be a headwind.
Shares jumped 9% to an intraday high of $1,111.08, settling at $1,102.20 on heavy volume.

2 days ago

CNBC

Lilly reports Q4 2025 earnings

LLY

Earnings

Dividends

Share Buyback

Delivered 43% revenue growth to $19.3 billion, driven by incretin analogs with the U.S. market up 33% and Lilly’s share at 60.5%.
Non-GAAP EPS rose 42% to $7.54.
R&D spend increased 26% to $3.8 billion, and capital investments jumped 55% to $7.8 billion YTD.
Returned $1.3 billion in dividends and $1.5 billion in share repurchases.
Achieved full FDA approval for Jaypirca, pediatric approval for Mounjaro, and reported positive Phase 3 data for retatrutide and orforglipron with submissions in over 40 countries.

2 days ago

Presentation

Eli Lilly reports strong Q4 2025 results and raises 2026 guidance

LLY

Earnings

Guidance Update

New Projects/Investments

2025 financial performance: full-year revenue of $65.2 billion (+45% YOY) and EPS of $24.21 (+86% YOY); Q4 revenue grew 43% YOY to support $7.54 EPS
2026 guidance update: revenue expected between $80 billion and $83 billion (midpoint +25%); non-GAAP margin of 46–47.5%; EPS forecast $33.50–$35.00
Capital returns: distributed $1.3 billion in dividends and repurchased $1.5 billion of shares in 2025
Manufacturing and R&D investments: committed over $55 billion to build out manufacturing since 2020, opened new sites in Wisconsin and North Carolina, and launched an AI co-innovation lab with NVIDIA

2 days ago

Transcript

Lilly reports Q4 2025 financial results

LLY

Earnings

Guidance Update

Revenue of $65.2 billion in 2025 (up 45% vs. 2024) and Q4 revenue growth of 43%; EPS of $24.21 for the year (+86%) and Q4 EPS of $7.54.
2026 guidance: revenue of $80–83 billion (≈25% midpoint growth), non-GAAP performance margin of 46–47.5%, and EPS of $33.50–35.00.
Pipeline progress: Orforglipron submitted for obesity in the U.S. and over 40 countries; retatrutide delivered 29% mean body-weight loss at 68 weeks; 36 active Phase III programs and 14 new Phase III trials initiated.
Capital allocation: $1.3 billion in dividends distributed and $1.5 billion in share repurchases in 2025.

2 days ago

Transcript

Eli Lilly reports Q4 2025 results

LLY

Earnings

Guidance Update

Revenue up 45% to $65.2 B in FY 2025, with Q4 revenue up 43% and EPS of $7.54 (vs $5.32 in Q4 2024)
2026 guidance: Revenue of $80 B–$83 B and EPS of $33.50–$35.00
Key products contributed over $13 B in Q4, growing 91% year-over-year, led by incretin therapies Mounjaro and Zepbound
Pipeline progress: submitted Orforglipron in the U.S. and over 40 countries for obesity, and reported positive Phase 3 data for Orforglipron and Retatrutide
Returned capital: $1.3 B in dividends and $1.5 B in share repurchases

2 days ago

Transcript

Eli Lilly posts strong Q4 2025 results, raises 2026 guidance

LLY

Earnings

Guidance Update

Revenue Acceleration/Inflection

Revenue of $19.29 B (+42–43% YoY) and non-GAAP EPS of $7.54, both beating expectations
Mounjaro sales up ~110% (US $4.1 B) and US Zepbound sales up ~122% (US $4.2 B) driving growth
2026 guidance raised to $80–83 B in revenue and non-GAAP EPS of $33.50–35.00
Management highlighted expanded manufacturing capacity and pipeline progress (including orforglipron)

2 days ago

Bloomberg

Eli Lilly reports Q4 2025 results and issues 2026 guidance

LLY

Earnings

Guidance Update

In Q4 2025, revenue reached $19.3 billion, up 43% year-over-year, driven by volume growth in Mounjaro and Zepbound.
Q4 2025 EPS was $7.39 reported (+51%) and $7.54 non-GAAP (+42%).
Full-year 2026 guidance set revenue at $80–$83 billion and non-GAAP EPS at $33.50–$35.00.
Regulatory progress included FDA approval of Kwikpen for tirzepatide, expanded Jaypirca indication, and submissions for orforglipron in obesity and diabetes.

3 days ago

8-K

Eli Lilly reports Q4 2025 results and issues 2026 guidance

LLY

Earnings

Guidance Update

Revenue Acceleration/Inflection

In Q4 2025, revenue grew 43% to $19.3 billion and reported EPS rose 51% to $7.39 ($7.54 non-GAAP), driven by volume growth from Mounjaro and Zepbound.
Mounjaro revenue jumped 110% to $7.4 billion, and Zepbound revenue increased 123% to $4.3 billion in the quarter.
For full-year 2026, Lilly guided revenue of $80–83 billion and non-GAAP EPS of $33.50–35.00, excluding intangible asset amortization and IPR&D charges.

3 days ago

Press Release

Lilly enters global R&D collaboration with Zonsen PepLib Biotech

LLY

New Projects/Investments

Eli Lilly and Zonsen PepLib Biotech Inc. entered a global R&D collaboration and license agreement to develop novel peptide-based drug candidates using PepLib’s proprietary libraries.
Under the agreement, PepLib will lead screening and identification of optimal peptide molecules, while Lilly will oversee IND-enabling studies, clinical development, and commercialization.
PepLib will receive upfront and near-term payments, and is eligible for development, regulatory, and sales milestones plus tiered royalties on future net sales.
The partnership merges PepLib’s peptide discovery platforms with Lilly’s global development and commercialization expertise to advance new therapeutics.

3 days ago

Press Release

Lilly selects Pennsylvania for new injectable medicine manufacturing facility

LLY

New Projects/Investments

Hiring

$3.5 billion investment to build a Lehigh Valley, PA, facility for next-generation weight-loss therapies, including retatrutide.
Facility will create 850 high-value jobs and generate 2,000 construction jobs, with operations starting in 2031.
Marks Lilly’s 10th U.S. manufacturing site since 2020 and 4th announced since February 2025, part of over $50 billion in capital commitments to expand U.S. capacity.